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Introduction
The cytokines interleukin (IL)-6, IL-1β, and tumor necro-
sis factor (TNF)-α are implicated in the production of 
C-reactive protein (CRP) by the liver.1 Low, but higher 
than normal, levels of these cytokines and CRP have been 
identified in the sera of patients with systemic lupus 
erythematosus (SLE).2 Although the serum levels of the 
three CRP-inducing cytokines (IL-6, IL-1β, and TNF-α) 
do not correlate with either CRP levels or the SLE 
Original Article
Changing Cytokine Patterns in Systemic Lupus: A Prospective 
Longitudinal Study
Lieh-Bang Liou*, Wan-Ju Chao
Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital at Lin-kou and 
 Chang Gung University College of Medicine, Tao-yuan, Taiwan.
BACKGROUND/PURPOSE: We have previously reported that lupus monocytes display distinctively 
differing patterns of C-reactive protein (CRP)-inducing cytokine interleukin (IL)-6, IL-1β, and tumor 
necrosis factor (TNF)-α secretion when stimulated with either immune complexes (ICs) or lipopolysac-
charide (LPS). In this study, we investigated whether the cytokine patterns of peripheral blood mononu-
clear cells (PBMCs) isolated from lupus patients acquired an IC or LPS pattern, either over time, or 
following corticosteroid or hydroxychloroquine use.
METHODS: PBMCs from lupus patients were obtained at 0, 1, 3, and 6 months post diagnosis and stim-
ulated with ICs or LPS. Cells were obtained for polymerase chain reaction to determine the IL-6, IL-1β, 
and TNF-α mRNA expression, and were assigned as having acquired either an IC or an LPS pattern.
RESULTS: Upon stimulation, the mRNA expression levels of the IL-6 and IL-1β were significantly higher in 
IC-pattern PBMCs than in LPS-pattern PBMCs (p = 0.021 and 0.028, respectively). Consistent with this, serum 
CRP levels in the IC-pattern group were significantly higher than those in the LPS-pattern groups (p = 0.027). 
Total serum CRP levels were positively correlated with serum C3c and C4 concentrations, and inversely 
correlated with serum anti-double stranded DNA (anti-dsDNA) levels. Conversely, circulating ICs were 
positively correlated with serum anti-dsDNA levels and inversely correlated with serum C4 concentrations.
CONCLUSION: Within the same individual, the CRP-inducing cytokine patterns can be changed, either 
naturally or after medication. Pre-existing serum circulating ICs are not predisposed to either IC or LPS 
cytokine patterns. Finally, CRP levels were correlated with anti-dsDNA consumption.
KEYWORDS: CRP-inducing cytokines, IC or LPS cytokine patterns, mononuclear cells, systemic lupus 
erythematosus
J Microbiol Immunol Infect 2010;43(1):18–25
Contents lists available at ScienceDirect
Journal of Microbiology, Immunology and Infection
Journal homepage: http://www.e-jmii.com
 19
Cytokine patterns change in SLE
disease activity index (SLEDAI) scores in SLE patients,2 
high serum CRP levels are associated with stimulation 
by immune complexes (ICs), and low levels have been 
shown to be associated with stimulation by lipopolysac-
charide (LPS).3 As Liou’s study was of a cross-sectional 
design, it is not known whether these cytokine secretion 
patterns remain constant over time, or whether they 
change — either naturally or by certain medications. This 
question underscores the importance of determining 
whether a lupus patient experiencing episodes of fever 
has an infection.4 Furthermore, it is unclear whether 
serum ICs affect particular cytokine patterns. To answer 
these questions, this study followed lupus patients from 
diagnosis to 6 months post-diagnosis. However, instead 
of using mono cytes,3 we used peripheral blood mono-
nuclear cells (PBMCs). This is because they are easier to 
isolate in high numbers, and they express IL-6, IL-1β, and 
TNF-α in a manner representative of the whole blood cell 
population.
Methods
Ethics approval
This research was approved by the Medical Ethics Com-
mittee of Chang Gung Memorial Hospital, Taoyuan 
County, Taiwan. Informed consent was obtained from 
each subject.
Patients’ clinical and laboratory profiles
From October 2003 to June 2004, nine lupus patients 
were enrolled in this longitudinal study. Of these, six were 
newly diagnosed (group 1; Table 2) and three had been 
treated for from 3 months to > 2 years (group 2; Table 3) 
prior to enrollment. The CRP concentration in serum 
(normal, < 5 mg/L) was measured by nephelometry using 
a low detection limit of 3.19 mg/L. None of the patients 
had any clinical serositis, arthritis, or cardiovascular 
events during the 6-month follow-up. Serum C3c (nor-
mal, 10–40 mg/dL), C4 (normal, 90–180 mg/dL), and IgG 
anti-double stranded DNA (anti-dsDNA) antibody (nor-
mal, < 35 IU/mL) concentrations were determined using 
nephelometry. SLEDAI-2K scores were derived according 
to a previously described method.5 Blood and laboratory/
clinical data were collected at specific time points, in the 
absence of infection.
Reagents
Human IgG and rabbit IgG were obtained from Sigma 
(St. Louis, MO, USA) and rabbit anti-human IgG was ob-
tained from Jackson ImmunoResearch (West Grove, PA, 
USA). RPMI-1640 medium and Hank’s balanced salt solu-
tion were purchased from Gibco (Grand Island, NY, USA). 
Fetal calf serum was obtained from Biological Indus tries 
(Kibbutz Beit Haemek, Israel) and heat-inactivated at 
56°C for 1 hour before use. TRIzol reagent was acquired 
from Invitrogen (Carlsbad, CA, USA). Circulating ICs were 
examined using a circulating ICs C1q ELISA assay kit 
(IBL, Hamburg, Germany) to quantitatively determine the 
level of circulating C1q- and IgG-containing ICs in human 
serum.
IC formation
ICs were generated as previously described.2 Briefly, 30 μg 
(or 60 μg) of human IgG in 0.5 mL phosphate-buffered sa-
line (PBS) was incubated in 24-well flat-bottomed plates 
(Co-star; Corning Incorporated, Corning, NY, USA) at 37°C 
for 2 hours. The wells were washed three times with PBS, 
followed by the addition of 30 μg (or 60 μg) of rabbit anti-
human IgG in 0.5 mL PBS to each well. The plate was kept 
at room temperature for a further 1.5 hours. The wells were 
again washed three times with PBS, and the adherent ICs 
formed used to stimulate PBMCs. Adherent rabbit IgG plus 
human IgG (30 μg) was used as a control for the ICs.
Cell culture and cell isolation
Each subject agreed to donate 25 mL blood at the time 
of diagnosis and then again 1, 3, and 6 months post-
disgnosis. Heparinized blood was processed and the cells 
separated.2 The PBMCs obtained were cultured with 
either medium alone, control ICs (rabbit IgG + human 
IgG at 30 μg), IC 30 (anti-human IgG + human IgG at 
30 μg), IC 60 (anti-human IgG + human IgG at 60 μg), LPS 
3 (3 μg/mL), or LPS 10 (10 μg/mL) for 48 hours.
Polymerase chain reaction (PCR)
The PBMCs were subsequently collected for mRNA extrac-
tion using TRIzol reagent (Invitrogen). mRNA (30 ng/μl) 
was subjected to reverse transcriptase-PCR amplification 
using the One step reverse transcription-PCR kit (Qiagen, 
Valencia, CA, USA). Primer sequences are listed in Table 
1.6,7 PCR conditions were as follows: reverse transcription 
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for 30 minutes at 50°C, and denaturation at 95°C for 
15 minutes, followed by 35 PCR cycles at 95°C for 59 sec-
onds, 54°C for 59 seconds, and 72°C for 59 seconds 
in a Mastercycler gradient 5331 (Eppendorf, Hamberg, 
Germany). Each PCR product (10 μL) were then electro-
phoresed on 2% agarose gels and band densities were de-
termined using a Fluor-STM MultiImager densitometer 
(BioRad, Hercules, CA, USA). The specificities of IL-6, 
IL-1β, and TNF-α PCR products were confirmed by se-
quence analysis.
Data were normalized as the ratio of cytokine/GAPDH 
(mean ± standard deviation) for comparison. The IC pat-
tern was determined at each time point (Tables 2 and 3) 
when the ratio of cytokine/GAPDH induced by the ICs di-
vided by cytokine/GAPDH induced by LPS was ≤ 1.00 for 
two or more of the three cytokines. The LPS pattern was 
determined for each time point (Tables 2 and 3) when the 
ratio of cytokine/GAPDH induced by the ICs divided by 
cytokine/GAPDH induced by LPS was > 1.00 for two or 
more of the three cytokines. These parameters were used 
because the expression levels of IL-6, IL-1β, and TNF-α in 
the PBMCs after challenge with ICs or LPS were not as 
distinctive as those for monocytes.3
Statistical analysis
Statistical analyses were undertaken using SPSS version 
12.0 (SPSS Inc., Chicago, IL, USA). Correlations were as-
sessed using Spearman’s correlation coefficient. Between-
group comparative analysis was performed using a χ2 test, 
Fisher’s exact test, Odds ratios, one-way analysis of variance 
(F-test), or the Mann-Whitney U test. A p value of < 0.05 
was considered statistically significant.
Results
One time point was counted as a unit for comparison or 
correlation. Thus 33 and 31 time points were available for 
correlating CRP versus SLEDAI and cytokine pattern ver-
sus CRP, respectively (Tables 2 and 3).
Effects of medication and disease on cytokine patterns 
in individual patients
The percentage of patients in group 1 showing a change 
in cytokine pattern between Month 0–1 was greater than 
that seen in group 2 over the same time period (75.0% vs. 
33.3%; Odds ratio = 6; 95% confidence interval, 0.22–162.54; 
Tables 2 and 3). There are no significant differences in the 
percentage of patients showing cytokine pattern changes 
between group 1 and 2 in time periods covering Month 
1–3 (or Month 3–6). Therefore, we suggest that natural 
course of the disease and/or medications taken by the pa-
tients may alter the cytokine patterns of lupus mononu-
clear cells.
Comparison of clinical and laboratory variables 
between the cytokine pattern groups
We next investigated whether the two different cytokine 
patterns were associated with differences in clinical and 
laboratory variables. Clinical symptoms did not differ be-
tween the IC- and LPS-pattern groups. For example, the 
frequency of arthritis did not differ significantly between 
the LPS-pattern and IC-pattern groups (4/20 vs. 0/13 sec-
tions; p = 0.10). A new rash was seen in 4/20 LPS-pattern 
patients and similarly in 2/13 IC-pattern patients (p = 
1.00). Other clinical symptoms had a considerably lower 
Table 1. Primer sequence used in this study6,7
Gene Primer Sequence
Human IL-6 forward 5-AAC TCC TTC TCC ACA AGC G-3
 reverse 5-TGG ACT GCA GGA ACT CCT T-3
Human IL-1β forward 5-GAC CTG GAC CTC TGC CCT CTG-3
 reverse 5-AGG TAT TTT GTC ATT ACT TTC-3
Human TNF-α forward 5-ATG AGC ACT GAA AGC ATG ATC-3
 reverse 5-TCA CAG GGC AAT GAT CCC AAA GTA GAC CTG CCC-3
Human GAPDH forward 5-TTT GCA GGG GGG AGC CAA AAG G-3
 reverse 5-GGA GTG GGT GTC GCT GTT GAA GTC-3
 21
Cytokine patterns change in SLE
Table 2. Clinical and laboratory data for group 1: newly diagnosed lupus patients
  Mo 0 Mo 1 Mo 3 Mo 6
1 SLEDAI 8 8 4 4
 CRP (mg/L) < 3.19 16.3 < 3.19 < 3.19
 Anti-dsDNA (IU/mL) 430 343 80 60
 Medicine None  Methylprednisolone Methylprednisolone Methylprednisolone
   (40 mg IV bid started) (12 mg qd for 3 wk) (6 mg qd for 2 mo)
 Cytokine patterna LPS ND LPS IC
2 SLEDAI 4 4 2 0
 CRP (mg/L) ND 6.00 < 3.19 < 3.19
 Anti-dsDNA (IU/mL) — — — —
 Medicine None HCQ HCQ continued;  Same, continued
   (200 mg qd for 1 mo) Prednisolone 
    (10 mg qd for 2 mo)
 Cytokine patterna LPS LPS LPS IC
3 SLEDAI 4 2 2 0
 CRP (mg/L) < 3.19 < 3.19 < 3.19 < 3.19
 Anti-dsDNA (IU/mL) 178 116 151 164
 Medicine None HCQ Same, continued Same, continued
   (200 mg qd for 1 mo)
 Cytokine patterna IC LPS IC LPS
4 SLEDAI 13 5 5 5
 CRP (mg/L) < 3.19 < 3.19 < 3.19 < 3.19
 Anti-dsDNA (IU/mL) 90 57 46 66
 Medicine None HCQ HCQ HCQ
   (200 mg qd for 1 mo) (300 mg qd for 2 mo) (400 mg qd for 3 mo)
 Cytokine patterna LPS IC LPS IC
5 SLEDAI 4 4 ND 16
 CRP (mg/L) 11.10  < 3.19 ND 39.20
 Anti-dsDNA (IU/mL) — — — —
 Medicine None HCQ None Prednisolone 
   (200 mg qd for 1 mo)  (15 mg qd for 3 wk)
 Cytokine patterna IC LPS ND  IC
6 SLEDAI 7 4 0 0
 CRP (mg/L) 16.50 6.84 6.73 88.80
 Anti-dsDNA (IU/mL) 45 97 151 193
 Medicine None HCQ Same, continued Same, continued
   (200 mg qd and  
   Prednisolone
   5 mg bid for 1 mo)
 Cytokine patterna LPS ND LPS IC
aImmune complex or lipopolysaccharide pattern was designated for each section when the ratio of IC-induced cytokine/GAPDH over LPS-
induced cytokine/GAPDH was > 1.00 or ≤ 1.00 for two or more of the three cytokines. SLEDAI = systemic lupus erythematosus disease activity 
index; CRP = C-reactive protein; Mo = month; IV = intravenous; bid = twice daily; qd = daily; LPS = lipopolysaccharide; IC = immune complex; 
ND = not determined; − = negative.
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frequency of occurrence than arthritis or a new rash, and 
there were no differences in the frequency of other clinical 
symptoms between the two pattern groups.
When all the time points were divided into groups 
based on SLEDAI scores > 7 (n = 4) and SLEDAI scores ≤ 7 
(n = 29), thus defining active or non-active lupus, as previ-
ously described,8 no differences were found in their corre-
sponding mRNA expression patterns (Tables 2 and 3; 
p = 3.84). Additionally, serum CRP levels were found to be 
uncorrelated with SLEDAI scores (Tables 2 and 3; p = 0.833 
for those with SLEDAI > 7, and p = 0.129 for those with 
SLEDAI ≤ 7). When all time points were taken into ac-
count, serum CRP levels were found to be uncorrelated 
with SLEDAI score (p = 0.882; n = 33). Serum CRP levels 
within the individual LPS or IC groups were also found to 
be uncorrelated with SLEDAI score (p = 0.300; n = 18 and 
p = 0.727; n = 13, respectively).
As expected, serum CRP levels in the IC-pattern groups 
were higher than those in the LPS-pattern groups (Table 4). 
However, no difference existed between the groups with 
respect to serum anti-dsDNA levels (data not shown). 
Notably, when all IC- and LPS-pattern groups were mixed, 
the serum CRP levels were positively correlated with serum 
C3c and C4 concentrations (Figure 1). Conversely, the 
CRP or C3c levels were negatively correlated with serum 
anti-dsDNA levels (Figure 1). In particular, the CRP con-
centrations within the subgroup with an anti-dsDNA con-
centration > 70 IU/mL was significantly lower than that in 
Table 3. Clinical and laboratory data for group 2: already treated lupus patients
  Mo 0  Mo 1 Mo 3 Mo 6
7 SLEDAI 4 ND 2 2
 CRP (mg/L) < 3.19 ND < 3.19 27.00
 Anti-dsDNA (IU/mL) 71 66 80 98
 Medicine Diagnosed and HCQ  HCQ  HCQ
  treated with HCQ (200 mg qd  (200 mg qd  (200 mg qd 
  (200 mg qd for 3 mo) & continued) & continued) & continued) &
  Prednisolone Prednisoline Prednisolone Prednisolone
  (10 mg qd for 2 mo) (7.5 mg qd for 1 mo) (5 mg qd for 2 mo) (2.5 mg qd for 1 mo)
 Cytokine patterna LPS LPS IC LPS
8 SLEDAI 2 2 0 0
 CRP (mg/L) 5.99 5.93 6.12 5.86
 Anti-dsDNA (IU/mL) — — – —
 Medicine Diagnosed and treated for Same, continued Same, continued Same, continued
  2.5 yr; HCQ (200 mg qd)
  & Prednisolone
  (2.5 mg qd for 3 mo)
 Cytokine patterna IC LPS LPS IC
9 SLEDAI 2 2 4 4
 CRP (mg/L) < 3.19 < 3.19 3.87 < 3.19
 Anti-dsDNA (IU/mL) 52 116 — —
 Medicine Diagnosed and treated for Same, continued Same, continued Same, continued
  > 3 yr; HCQ (200 mg qd)
 Cytokine patterna LPS LPS IC LPS
aImmune complex or lipopolysaccharide pattern was designated for each section when the ratio of IC-induced cytokine/GAPDH over 
LPS-induced cytokine/GAPDH was > 1.00 or ≤ 1.00 for two of the three cytokines. SLEDAI = systemic lupus erythematosus disease 
activity index; CRP = C-reactive protein; Mo = month; HCQ = hydroxychloroquine; qd = daily; LPS = lipopolysaccharide; IC = immune complex; 
− = negative.
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the subgroup with an anti-dsDNA concentration < 35 IU/
mL (Figure 2). Similarly, when all sections were divided 
into two subgroups [i.e. anti-dsDNA < 35 IU/mL (n = 12) 
and > 35 IU/mL (n = 19)], the former had higher serum 
CRP levels than the latter (p = 0.007).
Comparison of cytokine genes between 
cytokine-pattern groups
We then went on to examine whether the mRNA expres-
sion levels of the CRP-inducing cytokines in PBMCs 
differed between the two cytokine-pattern groups. In-
terestingly, following IC stimulation, the IL-6/GAPDH 
and IL-1β/GAPDH mRNA expression ratio was higher in 
the IC-pattern groups than in the LPS-pattern groups 
(Table 5). These experimental results indicate that PBMCs 
showing an IC-pattern of cytokine expression in lupus pa-
tients have constitutively express higher levels of the CRP-
inducing cytokine than LPS-pattern cells, mirroring the 
expression of cytokine proteins in lupus monocytes.3 How-
ever, no differences were observed in the CRP-inducing 
cytokine mRNA expression in either pattern group upon 
LPS stimulation (data not shown). Thus, with respect to 
combined serum CRP levels and cytokine gene patterns, 
individuals with an IC pattern are predisposed to higher 
serum CRP levels than those with LPS patterns.
Comparison of circulating ICs between groups and 
their correlations with laboratory parameters
We then looked at whether the cytokine patterns of PBMCs 
stimulated with IC or LPS were affected by the presence of 
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Figure 1. Correlation curves showing laboratory variables. When 
all immune complex and lipopolysaccharide pattern groups were 
mixed (n = 31), serum C-reactive protein levels were positively 
correlated with serum C3c at rho = 0.416 and with C4 at 
rho = 0.390 (p = 0.002, and p = 0.001, respectively). Additionally, 
serum CRP and C3c levels were negatively correlated with 
anti-double stranded DNA (anti-dsDNA) at rho = –0.599 and 
rho = −0.452 (p < 0.001 and p = 0.008, respectively). The x-axis 
represents real laboratory data without units. Different symbols 
on the same horizontal level represent data from one section. 
Therefore, when one set of data from a particular section had a 
high anti-dsDNA level (right side of the figure), its C3c, C4, and 
CRP levels were low (left side of the figure) and vice versa.
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Figure 2. Comparison of serum C-reactive protein levels between 
subgroups classified by different anti-double stranded DNA anti-
body levels. All 31 sections were divided into three subgroups, 
with cut-off points as shown on the x-axis (70 IU/mL was arbi-
trarily selected as twice the value of 35 IU/mL, which is the lower 
normal limit). Data presented as mean ± standard deviation. 
Box-whiskers indicate 25th–75th and 10th–90th percentiles. 
*p = 0.038 and a 95% confidence interval of 0.89–27.85.
Table 4. Comparison of serum C-reactive protein levels between immune complex-pattern groups and lipopolysaccharide-
pattern groups
 Immune complex induced (n = 13) Lipopolysaccharide induced (n = 18) p
Percentages < 3.19 mg/L (%) 53.8 66.7 0.226
C-reactive protein levels (mg/L)a 11.91 ± 25.47 (0–88.8) 3.79 ± 7.26 (0–27.0) 0.027b
aData presented as mean ± standard deviation (range), C-reactive protein levels < 3.19 mg/L was calculated as 0 mg/L; bF ratio = 5.395.
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pre-existing serum ICs. In cases where sera were obtained 
on the same day that gene experiments were carried out, 
the serum concentration of circulating ICs was 64.86 ± 
12.15 μg/mL in the LPS-pattern groups (n = 18; range, 
37.59–88.79) and 59.93 ± 15.50 μg/mL in the IC-pattern 
groups (n = 12; range, 20.74–80.66). These values were not 
significantly different (p = 0.446). Even when all time points 
were divided into those with SLEDAI > 7 (66.56 ± 31.25 μg/
mL, n = 3) and SLEDAI > 7 (63.05 ± 10.30 μg/mL, n = 28), 
no significant differences were found (p = 0.593). Notably, 
CIC concentration was positively correlated with serum 
anti-dsDNA antibody levels, and negatively correlated with 
serum C4 concentrations (CIC vs. CRP, p = 0.065; CIC vs. 
anti-dsDNA, p = 0.028; CIC vs. C3c, p = 0.314; CIC vs. C4, 
p < 0.001).
Discussion
In this study, we demonstrate that hydroxychloroquine, 
corticosteroids, and natural disease course can all alter 
the serum cytokine profiles in lupus patients (Tables 2 
and 3). Moreover, the classification of the different cy-
tokine patterns in this study was also reflected by the CRP 
differences in these patients (Table 4). This latter result 
for PBMCs confirms similar results obtained for using 
mono cyte subsets isolated from the peripheral blood of 
lupus patients.3 Although serum CRP levels were not sig-
nificantly correlated with SLEDAI scores in the different 
pattern groups (Tables 2 and 3), serum CRP levels were 
positively correlated with serum C3c and C4 concentra-
tions, and negatively correlated with anti-dsDNA anti-
body levels (Figures 1 and 2). These results imply that in 
the absence of infection CRP is synthesized in the liver of 
SLE patients (together with C3 and C4) only after tissue 
damage has occurred. In other words, low levels of C3, C4, 
and serum anti-dsDNA antibody levels appear following 
tissue damage, with a subsequent quick rebound in C3 and 
C4 production from the liver.2 In addition, only when anti-
dsDNA antibody concentrations declined (possibly due 
to deposition in the tissues or cells) did serum CRP levels 
increase (together with increased complement levels), con-
sistent with its role as an acute phase reactant (Figure 1). 
The clinical importance of this finding is highlighted by a 
recent study that suggests that reductions in anti-dsDNA 
levels are associated with concurrent ‘flares’ in patients 
with SLE.9 The time-gap (i.e. kinetic change over hours) 
between low serum anti-dsDNA levels and elevated serum 
CRP, C3, and C4 levels, must be considered as a focus of 
future research. Moreover, no serum complement data 
were shown that may have correlated with lupus disease 
“flares”, although flares were shown to correlate with re-
ductions in anti-dsDNA levels.9 Therefore, a considerably 
larger study is needed to confirm this observation. More-
o ver, whether combined CRP and anti-dsDNA levels accu-
rately reflect lupus flares, or whether serum CRP levels can 
be employed as an indicator for pathogenic anti-dsDNA 
antibodies needs to be clarified by future research.
High levels of IL-6 and IL-1β mRNA expression in the 
IC-pattern groups, in combination with higher mean CRP 
levels than in LPS-pattern groups (Tables 4 and 5), indi-
cate that, in the absence of infection, IC-pattern white 
blood cells have an intrinsic potential to generate a greater 
volume of CRP-inducing cytokines, as has been described 
previously for lupus monocytes.3 Since IC or LPS patterns 
are interchangeable under different conditions (Tables 2 
and 3), determining whether patients have an infection by 
analyzing CRP levels alone is difficult when no obvious 
source of infection exists. This is particularly true when 
serum CRP levels are < 60 mg/L.10 However, most patients 
in this study did not exhibit severe lupus disease activity 
(Tables 2 and 3; Figure 1) so a large patient population is 
required to confirm this hypothesis.
Table 5. Different cytokine mRNA expression after Immune complex stimulationa
Ratio Immune complex (n = 13) Lipopolysaccharide (n = 18) p
IL-6/GAPDH 203.55 (193.60–207.38) 191.63 (179.34–200.13) 0.028
IL-1β/GAPDH 196.10 (191.35–204.83) 183.60 (162.31–192.46) 0.003
TNF-α/GAPDH 171.45 (153.95–178.15) 164.88 (155.19–175.75) 0.921
aData presented as median (25th–75th percentiles) of the combined Immune complex stimulation (i.e. at 30 μg and 60 μg).
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Since pre-existing serum IC concentrations did not 
differ between the IC- and LPS-pattern groups, or among 
the different SLEDAI groups, CIC does not affect the pre-
disposition of lupus PBMCs to either IC or LPS patterns. 
Conversely, from a clinicopathological perspective, serum 
CIC concentrations may be an epiphenomenon for the 
anti-dsDNA antibody and complement interactions (see 
the end of the Results section).
A limitation of this study is the small number of pa-
tients enrolled. This drawback can be remedied, in part, 
by undertaking a longitudinal study over a greater time 
period, with a greater number of data points. However, in 
order to reliably confirm the findings of the present study, 
a further investigation with a considerably larger patient 
population will be necessary.
In summary, this is the first longitudinal study dem-
onstrating that CRP-inducing cytokine patterns in lupus 
PBMCs change over time, either naturally or as a result 
of medication. The results indicate that IC-pattern white 
blood cells have the inherent capability to secrete higher 
levels of CRP-inducing cytokines than LPS-pattern cells. 
Notably, serum CRP levels were positively correlated with 
serum C3c or C4 concentrations, and inversely correlated 
with serum anti-dsDNA antibody levels during the 
6-month follow-up period (Tables 2 and 3; Figure 1). This 
latter phenomenon is the first reported temporal relation-
ship among CRP, C3c, C4, and anti-dsDNA antibodies 
in lupus patients. However, studies examining a larger 
lupus population are needed to confirm these findings.
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